Metagenomi Therapeutics, Inc.
NMS: MGXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Metagenomi Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get MGX Z-Score →About Metagenomi Therapeutics, Inc.
Healthcare
Biotechnology
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
📊 Fundamental Analysis
Metagenomi Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -59.3% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -44.7%, which indicates that capital utilization is currently under pressure.
At a current price of $1.38, MGX currently trades near the bottom of its 52-week range (5%), indicating potential value or weakness (Range: $1.25 - $3.95).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$51.92M
Trailing P/E
--
Forward P/E
-0.83
Beta (5Y)
0.57
52W High
$3.95
52W Low
$1.25
Avg Volume
247K
Day High
Day Low